Navigation Links
SNM applauds FDA's decision to approve Zevalin
Date:9/10/2009

RESTON, Va.SNM applauds the U.S. Food and Drug Administration's (FDA) recent decision to approve the radioimmunotherapy (RIT) drug, Zevalin, as a front-line treatment of non-Hodgkin's lymphoma (NHL).

"This is welcome news for patients with non-Hodgkin's lymphoma," said Michael M. Graham, M.D., Ph.D., president of SNM and director of nuclear medicine at the University of Iowa Carver College of Medicine. "We've known for some time that RIT works extremely well for many NHL patients. With the FDA's approval, more patients can take advantage of this promising treatment sooner rather than later, giving them more hope for a brighter future."

This is the first time that the drug has been approved as an effective treatment option at the time of onset of lymphoma. Previously, Zevalin was approved only to treat lymphoma after a relapse, or after all conventional therapies failed. Now, patients with NHL can reap the same benefits earlier on in the disease, before it progresses to a more serious stage.

Non-Hodgkin's lymphomaone of the two main types of lymphomahas many different forms and is the fifth most common cancer in the United States. When lymphoma is first diagnosed, treatment choices depend on the cell type, extent of disease and rate of progression. New and emerging molecular imaging therapies, such as RIT, continue to provide major breakthroughs for patients with NHL by allowing tailored treatments at the molecular level. RIT is a more highly targeted therapy than traditional treatments because molecular imaging techniques and therapies can pinpoint the exact location of disease and deliver a tumor-killing dose of a radioactive substance directly to the cancer cells while sparing healthy cells.

"New developments in molecular imaging technologies are dramatically improving the ways in which lymphoma is diagnosed and treated," says Peter S. Conti, M.D., Ph.D., professor of radiology, clinical pharmacy and biomedical engineering at the University of Southern California's Keck School of Medicine. "Research in molecular imaging is also contributing to our understanding of lymphoma and helping to direct more effective care of patients with the disease."


'/>"/>

Contact: Amy Shaw
ashaw@snm.org
703-652-6773
Society of Nuclear Medicine
Source:Eurekalert

Related medicine news :

1. National Alliance for Hispanic Health Applauds President Obamas Efforts to Achieve Meaningful Health Care Reform in 2009
2. The American Heart Association Applauds Recommendations in New Childhood Obesity Report
3. HIMSS Electronic Health Record Association Applauds Federal Support of EHR Implementation for Hospitals and Physician Practices
4. NABP Applauds LegitScript and KnujOn for Spotlighting Exploitation of Internet Ad Programs by Rogue Internet Drug Outlets
5. Americans United for Life Applauds Decision Protecting Women From Dangers of RU-486
6. The Lupus Foundation of America Applauds New Legislation that Caps Out-of-Pocket Drug Costs
7. National Alliance for Hispanic Health Applauds Confirmation of Sonia Sotomayor as the Nations 111th Supreme Court Justice
8. The Scleroderma Foundation Applauds Introduction of First Bill in the Senate Promoting Research and Awareness of Scleroderma
9. GMA Applauds U.S. House for Passage of Landmark Food Safety Bill
10. Partnership Applauds Obamas No Cost-Sharing Protections for Preventive Services
11. APHA Applauds Congressional Action on Health Reform
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... ... TherapySites, the leading website and online marketing ... Association. This new relationship allows TherapySites to continue to extend their online ... and promotional offers. , "TCA is extremely excited about this new partnership, as ...
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in cancer care, and ... in the eye of the beholder, according to experts who offered insights and commentary ... of Managed Care. For the full issue, click here . , For the ...
(Date:6/26/2016)... ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is helping ... fitness app. The fitness app plans to fix the two major problems leading the fitness ... size fits all type program , They don’t eliminate all the reasons people ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library ... City Observer , brings up a new, often overlooked aspect of head lice: the parasite’s ... for fumigation is not a common occurrence, but a necessary one in the event that ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... June 24, 2016  Global Blood Therapeutics, Inc. (GBT) ... developing novel therapeutics for the treatment of grievous ... the closing of its previously announced underwritten public ... the public offering price of $18.75 per share. ... offered by GBT. GBT estimates net proceeds from ...
(Date:6/24/2016)... 24, 2016 ... the addition of the " Global Markets for ... This report focuses on ... updated review, including its applications in various applications. The ... which includes three main industries: pharmaceutical and biotechnology, food ...
(Date:6/24/2016)... -- The Academy of Managed Care Pharmacy (AMCP) today ... allow biopharmaceutical companies to more easily share health care ... coverage decisions, a move that addresses the growing need ... The recommendations address restrictions in the sharing of product ... a prohibition that hinders decision makers from accessing HCEI ...
Breaking Medicine Technology: